Marshall Wace
EBS icon

Marshall Wace’s Emergent Biosolutions EBS Stock Holding History

Marshall Wace’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-577,734
Closed -$4.8M – 3306
2026
Q1 		$4.8M Sell
577,734
-165,721
-22% -$1.72M ﹤0.01% 1327
2025
Q4 		$9.19M Sell
743,455
-168,933
-19% -$1.81M 0.01% 909
2025
Q3 		$8.05M Sell
912,388
-106,459
-10% -$828K 0.01% 1001
2025
Q2 		$6.5M Sell
1,018,847
-139,015
-12% -$795K 0.01% 1025
2025
Q1 		$5.63M Sell
1,157,862
-170,779
-13% -$1.41M 0.01% 1005
2024
Q4 		$12.7M Sell
1,328,641
-1,165,943
-47% -$10.7M 0.02% 712
2024
Q3 		$20.8M Buy
2,494,584
+1,951,771
+360% +$17.7M 0.03% 497
2024
Q2 		$3.7M Buy
542,813
+233,341
+75% +$1M ﹤0.01% 1123
2024
Q1 		$783K Buy
309,472
+231,294
+296% +$521K ﹤0.01% 1752
2023
Q4 		$188K Sell
78,178
-81,602
-51% -$192K ﹤0.01% 1989
2023
Q3 		$543K Sell
159,780
-25,784
-14% -$143K ﹤0.01% 1696
2023
Q2 		$1.36M Buy
185,564
+173,732
+1,468% +$1.61M ﹤0.01% 1598
2023
Q1 		$123K Buy
+11,832
New +$143K ﹤0.01% 2483
2022
Q3 		– Sell
-448,533
Closed -$13.9M – 3436
2022
Q2 		$13.9M Buy
+448,533
New +$15.3M 0.03% 657
2022
Q1 		– Sell
-20,519
Closed -$893K – 3496
2021
Q4 		$893K Sell
20,519
-102,200
-83% -$4.62M ﹤0.01% 2530
2021
Q3 		$6.14M Buy
122,719
+11,296
+10% +$684K 0.03% 824
2021
Q2 		$7.02M Buy
+111,423
New +$7.16M 0.03% 653
2020
Q1 		– Sell
-163,975
Closed -$8.85M – 1719
2019
Q4 		$8.85M Sell
163,975
-130,267
-44% -$7.07M 0.06% 340
2019
Q3 		$15.4M Buy
294,242
+218,936
+291% +$10.2M 0.12% 198
2019
Q2 		$3.64M Buy
+75,306
New +$3.61M 0.03% 589
2015
Q3 		– Sell
-16,729
Closed -$551K – 953
2015
Q2 		$551K Buy
+16,729
New +$519K 0.01% 693
2014
Q4 		– Sell
-33,002
Closed -$703K – 850
2014
Q3 		$703K Sell
33,002
-109,648
-77% -$2.51M 0.01% 603
2014
Q2 		$3.2M Buy
+142,650
New +$3.32M 0.05% 326

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Marshall Wace's EBS Position: Q2 2026 in Review

Marshall Wace sold out of Emergent Biosolutions (EBS) in Q2 2026, closing a stake of 577,734 shares — an estimated $4.8M sold.

Marshall Wace first reported a position in EBS in Q2 2014 and held it in 23 quarters. The position peaked at $20.8M in Q3 2024. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Marshall Wace reported no remaining Emergent Biosolutions position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 577,734 Emergent Biosolutions shares in Q2 2026, an estimated $4.8M.
  • Marshall Wace first reported a position in Emergent Biosolutions in Q2 2014 and held it in 23 quarters.
  • Marshall Wace's Emergent Biosolutions position peaked at $20.8M in Q3 2024.
  • 195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.